Navigation Links
Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
Date:10/30/2007

oor Baseline Prognostic Factors: Results of The Canadian POWeR Program; R. Bailey et al., Abstract 246, Saturday, Nov. 3, 2:00 pm, Exhibit Hall C

Low-Dose PEGINTRON Maintenance Therapy

Tolerability of Low-Dose Peginterferon Alfa-2b in Hepatitis C Patients with Cirrhosis: Results from the COPILOT Trial; M. Shah et al., Abstract 1322, Tuesday, Nov. 6, 8:00 am, Exhibit Hall C

Long-Term Low- Dose Treatment with Pegylated Interferon Alfa-2b Leads to a Significant Reduction in Fibrosis and Inflammatory Score in Chronic Hepatitis C Nonresponder Patients with Fibrosis or Cirrhosis; S. Kaiser, et al., Abstract 1311, Tuesday, Nov. 6, 8:00 am, Exhibit Hall C

Schering-Plough Sponsored CME Symposium

"Clinical Approaches to HCV Management: Community Cases, Expert Analysis" Monday, Nov. 5, 6:30-8:30 p.m., Sheraton Boston Hotel - Grand Ballroom and Liberty 39 Dalton Street, Boston

FACULTY:

Willis C. Maddrey, M.D. (Chair)

Professor of Internal Medicine and Executive Vice President for Clinical Affairs, The University of Texas Southwestern Medical Center at Dallas

Steven L. Flamm, M.D.

Associate Professor of Medicine and Medical Director, Liver Transplantation, Feinberg School of Medicine, Northwestern University, Chicago

John B. Gross, M.D.

Associate Professor of Medicine, Mayo Clinic College of Medicine Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minn.

Stephen Harrison, M.D.

Chief of Hepatology and Associate Program Director, GI Fellowship Brooke Army Medical Center, Fort Sam Houston, Texas

About PEGINTRON

In the United States, PEGINTRON is indicated for use alone or with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interfer
'/>"/>

SOURCE Schering-Plough
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
5. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
6. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
7. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
8. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
9. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...OMFIELD HILLS, Mich., Nov. 30 eHea...ite dedicated exclusively to products approved for...nt (FSA/HSA) claims. The site is also the first t...medications, saving shoppers up to 75 percent on e...lps cure two common healthcare headaches - high co...
(Date:11/30/2009)... BOZEN, Italy, November 30 Heal...Nstation,s development plans and product specifica...y Automated Parenteral,Nutrition", a new key compo...howcased at Las Vegas, ASHP (Booth # 114). , ...ustomers to the,TPNstation,s blueprints and to fin...
(Date:11/30/2009)... TEL AVIV, Israel, November 30 ...MRI-III(TM) dual channel microphone, the most adva...ional magnetic resonance imaging,(fMRI) environmen...ts a major step forward for fiber,optic microphone... ever, with,low-latency adaptive noise cancelling....
Breaking Medicine Technology:eHealthSource.com Launches Online Shopping Site Dedicated to Over-the Counter Medications Approved for FSA/HSA Claims 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 3New Generation Noise Cancelling Optical Microphone Paves Way for Advanced Brain and Speech Research 2UCLA School of Dentistry to build new cancer research facility 57080 1UCLA School of Dentistry to build new cancer research facility 57080 2UCLA School of Dentistry to build new cancer research facility 57080 3New book offers practical advice for unraveling the genetics of complex human diseases 9918 1New book offers practical advice for unraveling the genetics of complex human diseases 9918 2Secrets in a seed 3A Clues into the evolution of the first flowers 9913 1Secrets in a seed 3A Clues into the evolution of the first flowers 9913 2
...Tolerx, Inc., a,biopharmaceutical company engaged ...s for the treatment of immune-mediated diseases, a...e Ib clinical study of TRX1, a novel,humanized ant...refractory,cutaneous lupus erythematosus (CLE). Th..., tolerability, and pharmacokinetics of TRX1. Tole...
... Study of CGT-2168 Begins; Focus on Reducing GI ...y, MENLO PARK, Calif., Jan. 15 Cogentus Pharmace...t has been enrolled in the,company,s pivotal Phase...8.,The patient entered the study at the Mobile Hea...://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSL...
Other Medicine Technology:Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 2Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus 3First Patient Enrolled in Cogentus Pharmaceuticals' Pivotal Phase 3 Trial of Novel Combination Medicine 2
(Date:11/30/2009)..., Nov. 30 Mary Rita Hyland, Assist...SI Group, Inc., (SSI) has been elected to the 2010...change (WEDI). ,, Hyland has held a variety of...anization in 2001. She was initially charged with ...rance division and Business Continuity for SSI. Sh...
(Date:11/30/2009)...30 I,m surprised and dismayed by t...t every step of my life and my career as an attorn...Ombudsman for the Texas Youth Commission, I have u...ofessional commitment to the protection, preventio...rsonal passion. ,, Of the many concerns that ...
(Date:11/30/2009)...younger, immune cells than sedentary, healthy adul...s) -- Studies have shown that exercise can help wa...rch shows that the reason why may be found within ...nger telomeres -- DNA at the tips of chromosomes t... than healthy, nonsmoking adults who did not exerc...
(Date:11/30/2009)... by Merck, the unique online and mobile tool empow...V treatment decisions ,, ARLINGTON, Va., Nov. ...ody.com ), the #1 HIV/AIDS resource online, today ...ool offering HIV/AIDS-infected patients the abilit...he tool, created with sponsorship from Merck, is a...
(Date:11/30/2009)...s., Nov. 30 Harrington Physician S...of Family Practice physicians Martin Devine, Leah ...harlton practice. ,, These four esteemed and ... Fallon Clinic, will soon join the Harrington fami...dical office building under construction at 10 Nor...
Breaking Medicine News(10 mins):Health News:SSI Assistant Vice President Elected to WEDI Board 2Health News:Independent Ombudsman for Texas Youth Commission Resigns 2Health News:Exercise Guards White Blood Cells Against Aging 2Health News:Exercise Guards White Blood Cells Against Aging 3Health News:TheBody.com Launches My Health Tracker, Enabling HIV-Positive Patients to Track Lab Results, Medications and Supplements 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 3
...entara Heart Hospital and Sentara Virginia ..., TORONTO, April 8 /PRNewswire-FirstCall/ - Novad... real-time medical imaging and image guidance,syst...a Beach, Virginia have fully integrated the SPY(R)...
...e Huckabee Share Behavior Change Successes ..., PALM SPRINGS, Calif., April 8, 2008 Today, Hea...ange interventions with outcomes,kicked off ENGAGE... HealthMedia President and CEO Ted Dacko provided ...
...ampa-area company,Empower Technologies, has develo...that allows physicians to gain approval from insur...th patients as a result., As medical costs skyroc...complying with greater "red tape",demands., Empow...
... waking up since coffee, SPARTA, N.J., April 8, 2...ling refreshed and ready to go, you,re not alone. ...d school performance to spousal,relations and even...to wake up in the morning., Wake Up On Time was d...
...PRNewswire-FirstCall/ - Haemacure Corporation,(TSX...ping high-value human,therapeutic proteins for com...pecial Meeting of Shareholders on:, Date : .... Joseph Galli, Chairman & CEO of Haemacure, will ...
...ook in your,medicine cabinet -- do you spot prescr...g to the nation,s dramatic increase in irresponsib...tional Drug Control,Strategies Report, 71 percent ... marijuana use., (Photo: http://www.newscom.com/...
Other Medicine News:Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 3Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 4Health News:HealthMedia Kicks Off ENGAGE Conference 2Health News:HealthMedia Kicks Off ENGAGE Conference 3Health News:Tired Mother Invents Pill to Wake You Up On Time 2Health News:Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure 2Health News:Prescription Drug Abuse Threatens Availability of Pain Medication 2
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: